S. 5502: Protecting Biotechnology and Biomanufacturing as Critical Infrastructure Act
This bill would direct the Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency (CISA) to treat biotechnology and biomanufacturing infrastructure as part of the nation’s critical infrastructure protection work.
What changes the bill makes
- It amends existing homeland security law so CISA can focus more directly on protecting biotechnology and biomanufacturing facilities, systems, and related operations.
- It adds biotech and biomanufacturing infrastructure to the list of areas CISA can assess, support, and include in national critical infrastructure planning.
- For biotech and biomanufacturing areas that do not already have a designated “sector-specific agency” responsible for them, the bill directs CISA to take actions needed to protect them.
- It also requires CISA to coordinate its assessments with relevant information-sharing organizations and industry groups, such as BIO-ISAC and H-ISAC.
Required planning and reporting
The bill would require CISA’s Director to submit a work plan to Congress within 45 days after enactment. That work plan would need to include:
- an identification of key stakeholders in biotechnology and biomanufacturing infrastructure, including information-sharing organizations;
- a plan to make sure those stakeholders know whether they are already covered by existing critical infrastructure protection efforts;
- a plan to ensure those stakeholders are represented in relevant industry groups and coordinating councils; and
- a plan to update strategic homeland security plans by September 30, 2027, using input from those stakeholders.
After that, CISA would have to provide Congress with:
- a report within 1 year on how the work plan is being carried out; and
- a later report, due no later than 2 years after the work plan is submitted, on whether any important biotechnology areas still are not protected as critical infrastructure.
Practical effect
In plain terms, the bill would make the federal government more formally responsible for identifying, coordinating, and improving cybersecurity and infrastructure protections for biotechnology and biomanufacturing operations. It does not itself create new penalties or direct spending programs; instead, it mainly expands CISA’s role, requires planning, and sets deadlines for reports to Congress.
Relevant Companies
- AMGN — Amgen, a major biotechnology company, could be affected if the bill leads to new federal cybersecurity or infrastructure coordination expectations for biotech facilities and operations.
- BIIB — Biogen, as a large biotech manufacturer, could see indirect effects from any new infrastructure security standards, reporting, or industry coordination efforts.
- GILD — Gilead Sciences, which operates significant biopharmaceutical manufacturing and research activities, could be indirectly affected by expanded critical infrastructure attention to the sector.
- MRNA — Moderna could be impacted if federal protection efforts lead to additional coordination or security expectations for biomanufacturing and related supply chains.
- REGN — Regeneron, a biotechnology and biomanufacturing company, could be affected by federal efforts to classify and protect more of the sector as critical infrastructure.
- VRTX — Vertex Pharmaceuticals could be indirectly affected through sector-wide cybersecurity, infrastructure, and stakeholder coordination measures.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
2 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Sep. 24, 2026 | Introduced in Senate |
| Sep. 24, 2026 | Read twice and referred to the Committee on Homeland Security and Governmental Affairs. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.